| Gastro‑intestinal (GI) |
• Chronic stomach ulcers or bleeding • Gastric irritation, dyspepsia, constipation |
Inhibition of COX‑1 reduces protective prostaglandins in the GI tract. |
Persistent abdominal pain, black/tarry stools, vomiting blood, loss of appetite. |
| Cardiovascular (CV) |
• Elevated blood pressure • Edema (fluid retention) • Increased risk of heart attack or stroke (especially in people >60 or with pre‑existing CV disease) |
NSAIDs blunt prostaglandin‑mediated vasodilation and can raise renin, leading to sodium‑water retention and platelet aggregation. |
New or worsening chest pain, shortness of breath, swelling in legs, sudden high BP readings. |
| Renal (Kidney) |
• Decreased kidney function (especially in patients with existing CKD or dehydration) • Acute interstitial nephritis (rare) |
COX inhibition reduces renal blood flow and prostaglandin‑mediated vasodilation. |
Persistent fatigue, swelling, unexplained weight gain, decreased urine output. |
| Hepatic (Liver) |
• Elevated liver enzymes (transaminases) • Rare hepatic failure |
Diclofenac is largely metabolised by the liver; chronic exposure can overwhelm detox pathways. |
Persistent fatigue, jaundice, dark urine, pale stools. |
| Ophthalmic (Eye) |
• Cataracts, retinal changes with very long‑term use |
Chronic inflammation and oxidative stress may alter ocular tissues. |
Vision changes, blurred vision, difficulty adjusting to light. |
| Dermatologic (Skin) |
• Persistent rash or dermatitis, rare photosensitivity |
Immune‑mediated or allergic reactions that can become chronic. |
Red, itchy patches that do not resolve, swelling, blistering. |
| Central Nervous System (CNS) |
• Headaches, dizziness, rarely seizures |
Prolonged prostaglandin suppression may influence neurovascular dynamics. |
Persistent or worsening headaches, confusion, fainting spells. |